Should you buy Omeros stock now?
Yes, the technical signal for Omeros is currently Strong Buy. Omeros trades at $19.63 as of Oct 13, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.415 with falling momentum (signal: 0.499); RSI is at 57.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average). The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Omeros stock?
There is currently no active analyst price target for Omeros.
Is Omeros a dividend stock?
No, Omeros does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Omeros stock?
Omeros is rated as a stock in the risk category Conservative. the annual standard deviation is 0.0%, which classifies the stock as Conservative.
Is Omeros overvalued?
Omeros has the following valuation ratios: a P/E ratio of 16.3 (moderately valued), a P/S ratio of 37.4, a P/B ratio of 8.4.
Is Omeros overbought?
No, Omeros is not overbought. RSI is at 57.8 (neutral zone). The technical indicators show: RSI is at 57.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 3.1% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Omeros earnings report?
Omeros reports its next earnings on November 12, 2026. The stock currently trades at $19.63. With a P/E ratio of 16.3, the market will be watching closely whether earnings meet expectations.
Is Omeros shorted?
Yes, Omeros is shorted with 17.9% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Omeros stock?
No, insiders are not buying Omeros shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 10 sales. On a net basis, 1,736,548 $ worth of shares were sold. Across the last 17 reported transactions, the split is 2 purchases and 15 sales, with a net 2,598,973 $ sold. Active sellers include Borges David J., Cancelmo Peter B, HANISH ARNOLD C and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Omeros a good stock?
Based on our total score, Omeros is rated as a good stock with a total score of 79 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 43/100, Quality: 100/100, Momentum: 96/100. Whether now is the time to buy is a separate question: the technical signal is Strong Buy. Whether Omeros is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Omeros stock?
The outlook for Omeros based on current data: the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Nov 12, 2026, which can move the price; the P/E ratio is 16.3 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Omeros stock rising?
Omeros is rising right now. The technical indicators show: the price is 3.1% above the 20-day average; short interest is 17.9% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Omeros go?
There is currently no active analyst price target for Omeros. The stock has traded between $4.06 and $21.24 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Omeros fall?
The stock has traded as low as $4.06 over the last 52 weeks — that is 79.3% below the current price of $19.63. The biggest decline (drawdown) in the same period was 80.9% from high to low. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Omeros do?
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for ... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Omeros as an investment.
Did Omeros raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Omeros. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Omeros making money or losing money?
Yes, Omeros is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 324.9% — which is excellent. The operating margin (profit before interest and taxes) is 0.3%. At a P/E ratio of 16.3, you currently pay 16.3 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Omeros go bankrupt?
The bankruptcy risk of Omeros is rated as elevated. Altman Z2 (a model for assessing financial distress) is -4.60 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Omeros have a lot of debt?
Yes, Omeros has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.